Diffuse large B-cell lymphoma
Treatment options in Shanghai

Microscopic appearance is interpreted together with additional tests selected for the case. Immunohistochemistry and immunophenotyping help identify cell markers and lymphoma type; cytogenetic testing, including FISH, can examine particular genetic changes when relevant. These tests answer related but different questions, and a protein-marker result is not the same as a genetic rearrangement result. Ask which findings support the diagnosis, which results are still pending and whether an additional test could change classification or management. A second opinion does not mean every patient needs an identical extended test panel.

DLBCL treatment depends on precise classification. The value of a Shanghai second opinion is not simply another look at a slide, but a pathology review that informs the haematology decision. Ruijin Hospital, Shanghai Jiao Tong University School of Medicine has experience in blood-cancer diagnosis and treatment. Reviewing tissue, stains and genetic results alongside stage and treatment history can show which discrepancies would change care and which questions need another test.

If two reports differ, ask for a clear explanation of the specific disagreement: tissue adequacy, interpretation, classification or a result still requiring confirmation. The important output is not merely a new label, but what the finding changes and what remains uncertain. Ask whether the pathologists need to communicate and whether existing material can answer the question before considering another biopsy. Keep both reports and any addenda together. A clinically useful second opinion should help the hematologist reconcile the evidence, rather than leave the patient to choose between two unfamiliar technical descriptions.